Investment

R42 launches $14 million Longevity fund

We speak exclusively to Ronjon Nag about his first fund, targeting seed investments in Longevity AI and biotech. The world of Longevity-specific investment funds just...

Clene goes for gold, and goes public

Company targeting neurodegenerative disease with gold nanocatalyst technology goes public; multiple human trials ongoing for MS, Parkinson's and ALS. Salt Lake City biopharma company Clene...

A year in Longevity: different perspectives

Looking for anti-aging solutions in some unusual places. 2020 has seen Longevity.Technology covering a variety of news in the Longevity sector, from discoveries in the...

A year in Longevity: founders’ perspectives

Speaking to the innovators behind some of Longevity’s most exciting companies. Continuing our look back at some of the highlights of 2020, we thought we’d...

A year in Longevity: science perspectives

Longevity leaders on the key issues facing our sector. Over the past year, we’ve had the pleasure of speaking to some of the Longevity sector’s...

Human Longevity and the Final Frontier

World’s first Space and Longevity VC fund prepares for launch. A new rolling investment fund is gearing up to make its first Longevity investments in...

BioAge CEO: “It’s all about the data.”

BioAge's Kristen Fortney explains how focusing on human data will see two age-targeting drugs head to the clinic next year. Yesterday, the world again sat...

BioAge lands $90 million; gears up for clinical trials in 2021

Company also appoints Chief Medical Officer as it prepares to enter the clinic with two Phase 2-ready therapeutic compounds that target aging pathways. Longevity biotech...

The time is right for specialist Longevity investment

We speak to the co-founder of LongeVC – an investment firm focused exclusively on Longevity. Earlier this month, LongeVC emerged onto the scene with a...

Would you invest $1000 per week to live longer?

Money can't buy happiness - but it can buy Longevity;  this updated report from UBS identifies that investors are re-thinking where they invest their...

Exclusive: ChromaDex’s CEO on Longevity commercialisation

ChromaDex CEO Rob Fried on regulatory approval, scaling-up and going global. LA-based ChromaDex is a global bioscience company whose ethos is to improve the way...

AgeX Therapeutics reports Q3 financial results

AgeX commercialises its stem cell lines with continued support from stakeholder Juvenescence. Biotech AgeX Therapeutics reported financial and operating results for the third quarter ended...

Wearable firm switches focus to enterprise

Biostrap raising funds to open up consumer wearable tech for businesses to build their own biometric monitoring platforms. Since 2016, Los Angeles based wearable tech...

Helping professionals biohack personalised health

We speak to the founder of Aimee Health – currently raising seed funding for its nutrition monitoring AI platform. Californian nutrition health start-up Aimee Health is on...

Healthspan wearables and subscription services are hot!

Whoopee! Health monitoring firm bags $100 million in funding: WHOOP valued at $1.2 billion in Series E financing led by IVP. Health monitoring company WHOOP...

Proposed budget cut: reduced Longevity for EU citizens?

European Longevity Initiative writes an open letter addressing concerns that the European Research Council's budget has been cut. Suggested changes to the proposed ERC budget...

At-home wellness biomarker test to deliver instant results

ZiO Health seeks funding for subscription-based urine test that measures multiple health biomarkers. Biomedical start-up ZiO Health is on a mission to change how the...

Primetime Partners get ready for Longevity primetime

New VC firm seeks start-ups who are working to solve the “urgent problems” facing today’s aging society. This summer, a new venture capital firm was...

ARDD 2020: Addressing the challenges in drug discovery

We speak to the co-founder of Molecule about building a unique marketplace for early stage therapeutic development. Next week (September 1 - 4), the annual...

The billionaires are coming!

Longevity Investors Conference aims to focus the investment spotlight on developments in anti-aging science. As Greg Bailey told us last week: "When I was talking...
ChromaDex TruNiagen
whoop

Latest articles